BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas.
TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.